YOLFTbeta
Nykode Therapeutics ASA

Nykode Therapeutics ASA

NYKD · OL · Healthcare / Biotechnology

2.87NOK-0.02 (-0.87%)

Price History

Full chart

Market Stats

Previous Close2.89
Open2.89
Day Range2.87 – 2.95
52-Week Range1.70 – 5.20
Volume439.37K
Market Cap1.36B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.67
Dividend Yield0.00%
Beta0.84
50-Day Avg3.82
200-Day Avg3.24

About

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Michael Thyring Engsig
  • Employees59
  • HeadquartersOslo Science Park, Oslo, Norway, 0349, Norway
  • Websitehttps://nykode.com

Leadership

  • Mr. Michael Thyring EngsigChief Executive Officer · b. 1972
  • Dr. Agnete B. Fredriksen Ph.D.Co-Founder & Chief Scientific Officer · b. 1978
  • Mr. Harald GurvinChief Financial Officer · b. 1975
  • Mr. Jakob Helding RasmussenChief Technology Officer
  • Ms. Louise StubbeChief Legal Officer

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue24.04K9.76M12.04M12.40M215.00M33.96M7.17M12.90M8.68M0
Growth (%)-+40518.36%+23.34%+2.93%+1634.52%-84.20%-78.89%+79.99%-32.73%-100.00%
Gross Profit-9.76M12.04M12.40M215.00M33.96M7.17M12.90M8.68M-
Gross Margin-100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%-
Operating Expense-43.73M77.88M134.80M36.73M44.74M60.32M70.98M57.01M-
Operating Income-1.62M-33.97M-65.84M-122.40M178.26M-10.78M-53.16M-58.08M-48.33M-28.59M
Operating Margin-6752.21%-347.91%-546.73%-987.46%82.91%-31.73%-741.57%-450.18%-556.87%-
EBITDA--33.88M-65.78M-122.26M181.25M-10.25M-48.93M-41.74M-43.07M-15.53M
EBITDA Margin--347.05%-546.25%-986.33%84.30%-30.19%-682.59%-323.52%-496.30%-
Net Income-1.60M-31.37M-63.79M-120.23M149.77M-9.41M-42.74M-35.15M-38.82M-12.24M
Net Income Margin-6674.84%-321.31%-529.75%-969.97%69.66%-27.72%-596.30%-272.47%-447.30%-
R&D---60.84M10.63M16.30M26.77M29.36M14.73M13.40M
R&D as % of Total Revenue---490.86%4.94%47.99%373.52%227.55%169.77%-
Interest Expense009.20K24.04K46.00K130.00K241.00K224.00K188.00K125.00K
Interest Expense % of Total Revenue0.00%0.00%0.08%0.19%0.02%0.38%3.36%1.74%2.17%-

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets24.93M214.47M153.34M293.08M230.03M265.56M221.48M208.19M153.48M99.95M
Total Liabilities1.74M10.94M13.27M50.52M51.18M71.50M64.46M36.93M17.27M8.42M
Total Equity23.19M203.53M140.07M242.56M178.85M194.06M157.02M171.26M136.21M91.54M
Cash2.87M3.80M3.63M89.23M183.38M215.76M205.84M161.95M115.40M60.29M
Total Debt---790.07K284.00K7.17M5.51M5.73M3.44M-
Net Debt----88.44M-183.09M-208.59M-200.33M-156.23M-111.38M-

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.60M-62.78M-62.78M-92.08M180.27M1.16M-20.69M-96.62M-51.22M-29.46M
Investing Cash Flow28.88K-79.00K-79.00K-79.53M-6.02M10.75M11.05M7.04M6.93M3.52M
Financing Cash Flow2.35M337.00K337.00K227.08M-290.00K20.44M360.00K44.59M-1.40M-33.60M
Capital Expenditure6.43K79.00K79.00K667.17K99.00K871.00K2.67M1.90M71.00K38.00K
Free Cash Flow---62.86M-92.75M180.17M284.00K-23.37M-98.53M-51.29M-29.49M
Dividends Paid---------32.28M
FCF to OCF--100.13%100.72%99.95%24.59%112.93%101.97%100.14%100.13%
Dividend Paid to FCF----------109.44%

Earnings

Report DateNov 17, 2020May 11, 2021Aug 26, 2021Nov 17, 2021May 16, 2022Aug 24, 2022Nov 23, 2022Feb 28, 2023May 12, 2023Aug 22, 2023Nov 15, 2023Feb 28, 2024May 14, 2024Aug 21, 2024Nov 26, 2024Feb 26, 2025May 27, 2025Aug 27, 2025Nov 23, 2025Feb 25, 2026May 27, 2026Aug 26, 2026Nov 25, 2026
EPS Estimate--------0.41-0.53-0.52-0.64-0.54-0.54-0.50-0.48-0.68-0.23-0.23-0.25-0.25---
EPS Actual-0.16-0.19-0.18-0.230.32-0.28-0.51-0.41-0.43-0.32-0.32-0.21-0.52-0.21-0.34-0.22-0.050.03-0.10-0.25-0.12-0.21-
Surprise-------0.00%18.87%38.46%50.00%61.11%3.70%58.00%29.17%67.65%78.70%111.78%60.00%1.12%---
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap1.36B
Enterprise Value1.13B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2932.38
Price / Book2.03
EPS-0.67
Book Value2.28
Revenue (TTM)464.00K
Gross Profit (TTM)464.00K
EBITDA-26.94M
Profit Margin0.00%
Operating Margin-6363.21%
Return on Equity-25.06%
Return on Assets-17.48%
Shares Outstanding391.55M
Shares Float214.19M
Beta0.84
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20251×
1.00May 27, 2025